Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Creative Life Science CoROCO:7837 20 Return-on-Tangible-Equity is 24.21% as of Dec. 2025, which is 10% above its 10-year median of 21.96. GuruFocus rates ROCO:7837 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,199 Biotechnology companies, Creative Life Science Co ranks better than 91.33% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Creative Life Science Co's annualized net income for the quarter that ended in Dec. 2025 was NT$142 Mil. Creative Life Science Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$588 Mil. Therefore, Creative Life Science Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 24.21%.
The historical rank and industry rank for Creative Life Science Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:7837'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 18.66 Med: 21.96 Max: 36.97
Current: 20.9
During the past 5 years, Creative Life Science Co's highest Return-on-Tangible-Equity was 36.97%. The lowest was 18.66%. And the median was 21.96%.
ROCO:7837's Return-on-Tangible-Equity is ranked better than 91.33% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs ROCO:7837: 20.90
Creative Life Science Co (ROCO:7837) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Creative Life Science Co Return-on-Tangible-Equity Related Terms
Creative Life Science Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Creative Life Science Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Life Science Co Return-on-Tangible-Equity Chart
ROCO:7837 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Creative Life Science Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Life Science Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Creative Life Science Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Creative Life Science Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 24.21% mean?
Creative Life Science Co (ROCO:7837) has a Return-on-Tangible-Equity of 24.21% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Creative Life Science Co and its competitors. This is 10% above median its historical median of 21.96. Over the past decade, Creative Life Science Co's Return-on-Tangible-Equity has ranged from 18.66 to 36.97. According to the industry distribution chart, Creative Life Science Co ranks #104 out of 1199 companies in the Biotechnology industry, placing it in the top 8.7%.
Is Creative Life Science Co's Return-on-Tangible-Equity too high?
Creative Life Science Co's current Return-on-Tangible-Equity of 24.21% is 10% above median its 10-year median of 21.96. Over the past 10 years, this metric has ranged from a low of 18.66 to a high of 36.97. Based on the distribution chart, Creative Life Science Co ranks #104 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Creative Life Science Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Creative Life Science Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Creative Life Science Co ranks #104 out of 1199 companies for Return-on-Tangible-Equity. This places Creative Life Science Co in the top 9% of its industry — outperforming the majority of peers. Historically, Creative Life Science Co's own Return-on-Tangible-Equity has ranged from 18.66 to 36.97 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Creative Life Science Co and its competitors. Creative Life Science Co's current Return-on-Tangible-Equity is 24.21%, which is 10% above median its own 10-year median of 21.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Life Science Co stock overvalued right now?
Creative Life Science Co (ROCO:7837) has a current Return-on-Tangible-Equity of 24.21%. The current Return-on-Tangible-Equity is 24.21%, which is 10% above median its 10-year median of 21.96. Creative Life Science Co's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Creative Life Science Co (ROCO:7837), the current Return-on-Tangible-Equity is 24.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Creative Life Science Co Ltd is engaged in providing products of microbiology, and it has prepared media products and diagnostic reagents. The main products of CMP (Creative Media Plate) are solid and liquid media, which can be used for clinical microbiology, basic microbial research, environmental monitoring, biosafety testing, and quality control. Its product line is Transport Medium, Prepared Tube Media, Prepared Plated Media, VTM & I-VTM, Bacterial strain preservation system, and CMP SteriPack triple wrapped media.
20GF Score
Get the complete analysis for ROCO:7837
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7837 has been successfully added to your 
